ATP-dependent SWI/SNF chromatin remodeling complexes regulate cell-cycle and play critical roles in a variety of differentiation pathways. The core subunit SNF5/INI1 is a tumor suppressor that is inactivated in a highly aggressive childhood cancer of unknown cellular origin, termed malignant rhabdoid tumor (MRT). The highly undifferentiated phenotype of this tumor suggests that the loss-of-function of hSNF5/INI1 impairs specific differentiation programs of the MRT parental cell. Based on the hypothesis that these programs might be reinitialized upon hSNF5/INI1 re-expression in MRTs, we show that some MRT cell lines can differentiate toward the adipogenic lineage. We further show that the knock down of the SNF5/INI1 subunit abrogates adipocyte differentiation of murine 3T3-L1 preadipocytes and of human mesenchymal stem cells. Finally, we provide evidence that hSNF5/INI1 cooperates with C/EBPb and PPARc2 transcriptional regulators to activate the expression of adipocyte-specific genes. These data indicate that not only the ATPase subunit of the SWI/SNF complex, but also SNF5/INI1 is required for adipocyte differentiation. They further show that MRT cell lines harbor an adipogenic differentiation potential and that the tumor suppressor role of the SNF5/INI1 subunit may rely on its ability to regulate the balance between cell proliferation and differentiation.
Introduction
SWI/SNF complexes are evolutionarily conserved and modulate chromatin structure through ATP-dependent nucleosomal remodeling (Carlson and Laurent, 1994) .
Different SWI/SNF complexes with variable subunit compositions have been described in mammals (Wang et al., 1996) . They play a major role in transcription regulation through physical and functional interactions with transcriptional activators or repressors (Sif et al., 2001) and are involved in a variety of cellular processes, including the regulation of cell growth and differentiation (Roberts and Orkin, 2004) . In particular, SWI/ SNF-mediated chromatin remodeling is essential for the myeloid, erythropoietic, adipogenic, neuronal or myogenic differentiation pathways (de la Serna et al., 2006) . SWI/SNF complexes contain core subunits that are sufficient to remodel nucleosomes in vitro (Phelan et al., 1999) . This core complex includes an ATPase subunit, being either BRG1 or BRM, BAF155/BAF170 and SNF5/INI1. This last subunit, also termed BAF47 or SMARCB1, is encoded by a tumor suppressor gene that is almost always inactivated in a group of highly aggressive childhood cancers of unknown cellular origin termed malignant rhabdoid tumors (MRT) (Kalpana et al., 1994; Muchardt et al., 1995; Versteege et al., 1998; Biegel et al., 1999) . These tumors may occur in various organs including kidney, central nervous system (atypical teratoid and rhabdoid tumors, ATRT), liver, skin and soft tissues. The constitutional mutation of hSNF5/ INI1 is associated with a strong predisposition to develop these tumors (Sevenet et al., 1999) . Mouse models have confirmed this tumor suppressor role: whereas Snf5/Ini1 homozygous deletion is embryonic lethal, heterozygous mice develop tumors that closely resemble MRTs and that demonstrate loss of heterozygosity of the wild-type allele (Klochendler-Yeivin et al., 2000; Roberts et al., 2000; Guidi et al., 2001) . In the adult mouse, the conditional inactivation of Snf5/ Ini1 leads to a rapid death with profound organ failures, in particular of the hematopoietic system, leading to the hypothesis that SNF5/INI1 subunit is required for the survival of numerous cells in vivo (Roberts et al., 2002) . In vitro, it has also been shown that the inactivation of Snf5 impairs cell growth and survival of MEFs (Klochendler-Yeivin et al., 2006) . These data indicate that, depending upon the cell background, the SNF5/ INI1 subunit may be critical for cell survival or tumor suppression.
This last role is mediated, at least in part, by an antiproliferative activity. Indeed, several groups have documented that hSNF5/INI1 re-expression in MRT cell lines leads to the accumulation of cells in the G 0 /G 1 phase of the cell-cycle (Betz et al., 2002; Versteege et al., 2002; Zhang et al., 2002) . This hSNF5/INI1-induced cell-cycle arrest requires a functional RB/E2F pathway and is reversible (Medjkane et al., 2004) . In addition to its role in the G 1 /S transition, the loss-of-function of hSNF5/INI1 disturbs mitotic checkpoint control and induces subsequent chromosomal instability (Vries et al., 2005) . The tumor suppressor role of the SNF5/ INI1 subunit may not be limited to cell-cycle regulation but may also rely on cytoskeleton organization and DNA damage signaling (Medjkane et al., 2004; Klochendler-Yeivin et al., 2006) . Finally, a role for SNF5/ INI1 in differentiation is suggested by recent data showing that the liver-specific inactivation of Snf5/Ini1 in mice compromises hepatocyte differentiation (Gresh et al., 2005) .
Given the undifferentiated phenotype of MRT tumors and the major role of SWI/SNF complexes in a variety of cell fates, it is likely that the loss-of-function of hSNF5/ INI1 impairs specific differentiation programs of the MRT parental cell. We recently showed that hSNF5/INI1 may play a role in neural differentiation processes (Albanese et al., 2006) . In the present study, based on the hypothesis that hSNF5/INI1 re-introduction in MRTs may reinitialize specific differentiation processes of the MRT parental cell, we document a role for hSNF5/INI1 in adipogenesis, shedding new light upon its mechanisms of tumor suppression.
Results

Adipogenic potential of hSNF5/INI1-expressing MRT cell lines
In addition to cell-cycle arrest, ectopic expression of hSNF5/INI1 in rhabdoid MON cells is associated with dramatic morphological changes (Medjkane et al., 2004) . We further investigated these changes using a tetracycline-based hSNF5/INI1-inducible expression system (I2a cells) derived from the MON cell line. Upon tetracycline withdrawal, cells underwent a reversible arrest in the G 1 phase of the cell-cycle and the hSNF5/ INI1 protein was stably expressed over time (Figure 1a) . At late time points (12 days), a cell rounding was observed (Figure 1b, upper panel) . This was associated with the appearance of small vesicles that could be detected by phase-contrast microscopy and shown to stain positive with Oil Red O (ORO), a marker specific for lipid droplets (Figure 1b Figure 1c ). We next investigated whether this adipogenic feature was also observed in other MRT cell lines. To overcome low transfection efficiencies, we generated a retroviral vector (pWZL-INI1) encoding both the wild-type hSNF5/INI1 and the blasticidin resistance genes. The expression level of hSNF5/INI1 protein in blasticidinresistant cells was similar to that in the I2a inducible system (see KD cell line, Figure 1a ) and the protein was efficiently integrated in the SWI/SNF complex as shown previously (Medjkane et al., 2004) . As expected, all hSNF5/INI1-expressing MRT cell lines exhibited cellcycle arrest. As shown previously, for the MON cell line, no senescence-associated b-galactosidase staining was observed following hSNF5/INI1 expression in KD cells, whereas the control lysosomal b-galactosidase was strongly positive (data not shown). In the KD cell line, a strong ORO staining was detected in pWZL-INI1 but not in empty pWZL infected cells (Figure 1d ). In the Wa2 cell line, the ORO staining was already observed in the absence of hSNF5/INI1 and was not significantly modified after hSNF5/INI1 transduction (Figure 1e ). We conclude that at least a subset of MRT cell lines harbor an adipogenic potential that can be stimulated by hSNF5/INI1 re-expression.
To gain further insight into this adipogenic phenotype, we analysed the expression of adipocyte-specific genes upon hSNF5/INI1 viral transduction. These genes included peroxisome proliferator-activated receptor g2 (PPARg2), a nuclear receptor, which is a key regulator of adipocyte differentiation, and two markers of terminal differentiation, lipoprotein lipase (LPL) and aP2, an adipocyte-specific fatty acid-binding protein. A strong induction of all three markers was observed in hSNF5/INI1-expressing KD cells (Figure 2) . In Wa2 cells, PPARg2 was strongly induced by hSNF5/INI1 whereas LPL and aP2 exhibited only slight induction, aP2 being already expressed in parental Wa2 cells (Figure 2) . Finally, PPARg2, LPL and aP2 were not detected in hSNF5/INI1-transduced MON cells (Figure 2) . However, these three genes were induced when hSNF5/INI-expressing MON cells were incubated in an adipogenic differentiation medium (Figure 2 ). In KD and Wa2 cells, no additional effect of the differentiation cocktail was observed as compared to hSNF5/INI1 alone (data not shown). These data indicate that MRT cell lines can express late adipogenic markers spontaneously and even more strikingly after hSNF5/INI1 expression alone or in combination with a differentiation cocktail. They also suggest that hSNF5/INI1 may play a critical role in the regulation of adipogenesis.
Requirement for SNF5/INI1 in adipogenic differentiation models
To further investigate the role of this subunit in adipocyte differentiation, we performed knock-down experiments in the 3T3-L1 preadipocyte mouse model. 3T3-L1 cells were infected with lentiviruses encoding shRNA specific for mouse Snf5/Ini1 together with the puromycin resistance gene. A puromycin resistant population of 3T3-L1 cells with a strong decrease of the Snf5/Ini1 protein expression was generated ( Figure 3a ). This low level of Snf5/Ini1 remained stable along passages. Immunoprecipitation experiments showed that Baf155 and Baf170 could interact with Brg1, independently of Snf5/Ini1, suggesting that the SWI/SNF complex-or at least the Brg1 associated core (Figures 3b and c) . These data show that Snf5/Ini1 knock-down abrogates 3T3-L1 terminal adipocyte differentiation. Interestingly, Snf5/Ini1 knocked-down 3T3-L1 cells also exhibited a higher proliferation rate than control cells with an increased fraction of the cells in the S phase of the cell-cycle ( Figure 3d ).
To assess the requirement for the SNF5/INI1 subunit in another adipocyte differentiation model, its expression was knocked down in freshly prepared primary mesenchymal stem cells (MSCs) isolated from human bone marrow. Two days after infection with lentiviruses encoding hSNF5/INI1-specific shRNA, primary human MSCs were selected with puromycin and the differentiation cocktail was added 2 days later. A strong decrease of the hSNF5/INI1 protein level was observed ( Figure 4a ) and after a 7-day incubation in the differentiation medium, a trypan blue staining confirmed the excellent viability of both control and hSNF5/INI1-knocked-down cells. Upon hSNF5/INI1-knock-down, fat droplet accumulation was severely impaired (Figure 4b ) and the activation of LPL and aP2 but not that of PPARg2 was dramatically decreased (Figure 4c ). Taken together, the results obtained in these two systems establish that the SNF5/INI1 subunit is necessary for adipogenic differentiation.
hSNF5/INI1 cooperates with C/EBPb and PPARg2 C/EBP transcription factors are critical regulators of adipocyte differentiation (Lane et al., 1999) . In the 3T3-L1 model, C/EBPb and C/EBPd are rapidly activated upon induction of differentiation. They in turn induce C/EBPa and PPARg2, which together activate the majority of genes expressed in differentiating adipocytes (Rosen and MacDougald, 2006) . To address the molecular mechanisms underlying hSNF5/INI1-mediated adipogenic differentiation, we investigated the expression To further study the cooperation between hSNF5/ INI1 and C/EBPb, we carried out transcription activation reporter assays with the PPARg2 promoter, which has been described previously to contain C/EBP binding sites and to be activated by C/EBP proteins (Saladin et al., 1999) . Enforced expression of C/EBPb or hSNF5/ INI1 alone was not sufficient to activate a PPARg2 reporter construct in MON cells. In contrast, a potent induction was observed when hSNF5/INI1 was coexpressed with C/EBPb (Figure 5c ). We further addressed the issue of the binding of these factors on the endogenous PPARg2 promoter. ChIP experiments were performed in KD cells, which express a high C/EBPb level and in which hSNF5/INI1 expression is sufficient to induce PPARg2. They further showed that hSNF5/INI1 and C/EBPb were bound to the endogenous PPARg2 promoter (Figure 5d) . Interestingly, the binding of C/EBPb was not dependent upon the presence of hSNF5/INI1.
We also investigated a possible cooperation between hSNF5/INI1 and PPARg2 to activate the aP2 target gene, the promoter of which has been shown to contain PPARg2-responsive elements (Tontonoz et al., 1994) . In both MON and KD, PPARg2 expression alone was not sufficient to induce aP2 (Figure 6a ). In contrast, a very strong induction was observed after enforced expression of both PPARg2 and hSNF5/INI1, suggesting that PPARg2 activity requires hSNF5/INI1. This cooperation between hSNF5/INI1 and PPARg2 on the aP2 promoter was confirmed by reporter assay experiments (Figure 6b ). Finally, ChIP experiments showed that both hSNF5/INI1 and PPARg2 were recruited at the endogenous aP2 promoter upon hSNF5/INI1 expression in KD cells (Figure 6c ). Taken as a whole, these results indicate that two master transcriptional regulators of adipogenic differentiation, that is C/EBPb and PPARg2, are functionally dependent upon hSNF5/INI1 to induce adipocyte-specific genes.
Discussion
It has been shown previously that C/EBPa, C/EBPb and PPARg2 require the SWI/SNF ATPases BRG1 and hBRM to induce the adipogenic differentiation of uncommitted fibroblasts (Pedersen et al., 2001; Salma et al., 2004) . However, the requirement for other SWI/ SNF subunits was not investigated. Here, we use two well-characterized adipocyte differentiation models, namely murine committed 3T3-L1 preadipocytes and human mesenchymal stem cells, to analyse the role of the SNF5/INI1 subunit in this process. Our data show SNF5/INI1 regulates adipocyte differentiation J Caramel et al that, in both models, the knock-down of SNF5/INI1 abrogates differentiation toward the adipogenic lineage, therefore demonstrating that this SWI/SNF core subunit is critically required for adipogenesis.
At the molecular level, we show that C/EBPb or PPARg2 alone cannot induce some of their critical endogenous targets in hSNF5/INI1-deficient MRT cell lines, whereas this activity is restored by coexpression of hSNF5/INI1. More precisely, our reporter assays show that hSNF5/INI1 cooperates with C/EBPb to activate the PPARg2 promoter. ChIP assays further document that this activation is associated with a binding of hSNF5/INI1 and C/EBPb at the endogenous promoter. The current model proposes that C/EBPb binds the PPARg2 promoter, and then recruits SWI/SNF, the ATPase activity of which is required for transcription activation (Kowenz-Leutz and Leutz, 1999; Salma et al., 2004) . Our results further indicate that, in MRTs, C/EBPb binding at the PPARg2 promoter is achieved in the absence of hSNF5/INI1 but that PPARg2 induction only occurs upon hSNF5/INI1 binding. Similarly, the cooperative effect of hSNF5/INI1 and PPARg2 on aP2 induction is associated with a binding of these two factors on its promoter. However, since PPARg2 is strongly induced by hSNF5/INI1 expression, we cannot presently conclude whether PPARg2 requires hSNF5/INI1 for binding or, like C/EBPb, just for activation. Altogether, our results indicate that SNF5/ INI1 is critical for both early (C/EBP-mediated) and late (PPARg2-mediated) gene activation events and subsequent terminal adipocyte differentiation. They therefore strongly support the hypothesis of SNF5/INI1 being required for SWI/SNF function in adipocyte differentiation. Since SNF5/INI1 is not required for the assembly of the SWI/SNF complex in 3T3-L1 cells, its role may rather rely on the enhancement of the SWI/SNF remodeling activity, as suggested by in vitro studies (Phelan et al., 1999) or/and on the recruitment of other proteins necessary for C/EBP-and PPARg2-mediated transcription initiation.
However, whereas PPARg2 expression is strictly dependent on the presence of hSNF5/INI1 in 3T3L1 and MRT cell lines, it is still induced when hSNF5/INI1 is knocked down in MSCs (Figure 4c) . One of the hypotheses to account for this observation may rely on the residual expression of hSNF5/INI1 following knock down that may be sufficient to sustain PPARg2 expression in MSCs. Alternatively, other chromatin remodeling complexes or other key transcription factors, which promote adipogenesis (Farmer, 2006) may be involved in PPARg2 expression and compensate for hSNF5/INI1 depletion in MSCs.
Another important conclusion of the present study is that some MRTs harbor an adipogenic potential. 
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Indeed, in the KD cell line, hSNF5/INI1 alone is sufficient to induce both expression of terminal differentiation markers and accumulation of lipid vesicles. The adipogenic conversion of MON cells is less pronounced since expression of terminal differentiation markers requires hSNF5/INI1, but also either incubation with a hormonal cocktail, or cotransfection with C/EBPb or even more efficiently with PPARg2. In Wa2 cells, hSNF5/INI1 is required to induce PPARg2. However, some adipogenic features, including ORO staining and aP2 expression, are observed in the absence of hSNF5/INI1 in these cells. To account for this apparent contradiction, we may propose that hSNF5/INI1 is required for the induction but not for the maintenance of important adipocyte differentiation markers. Such a phenomenon has been recently described in epidermal development and differentiation (Kashiwagi et al., 2007) . Indeed, the ATP-dependent chromatin remodeler Mi-2b is required for the initial patterning of the expression of signaling molecules involved in follicular morphogenesis. Once established, basal cells subsequently deleted for Mi-2b can sustain epidermal differentiation and expansion. This suggests that, although chromatin remodeling may be necessary to induce expression, some promoters may then achieve a permissive, stable structure adapted to continued transcription in the absence of the initial chromatinremodeling factor. In MRTs, the ultimate adipogenic phenotype of tumor cells may be dependent on the time at which hSNF5/INI1 was lost. In this hypothesis, the genetic lesion leading to hSNF5/INI1 loss-of-function may have occurred later in the Wa2 than in the KD precursor, at a stage where adipogenesis was already induced.
MRTs constitute a group of tumors that may arise in various tissue localizations and that may exhibit a variety of phenotypic markers raising the question of their cellular origin. The adipogenic potential evidenced by the present work suggests that at least a subset of MRTs belongs to the mesenchymal lineage, which includes adipocytes, osteocytes and chondrocytes. Interestingly, the balance between adipogenic and osteogenic lineages is regulated by C/EBP factors (Hata et al., 2005) and SWI/SNF is also required for Runx2-dependent osteoblast-specific gene expression (Young et al., 2005) . Moreover, RhoA activity, which is inhibited by hSNF5/ INI1 (Medjkane et al., 2004) , regulates the commitment of mesenchymal stem cells to the adipocyte or osteoblast (c) KD cells were infected with empty pWZL (À) or pWZL-INI1 ( þ ) and subjected to 7 days of blasticidin selection. Chromatin immunoprecipitation assays of hSNF5/INI1 and PPARg2 were performed with specific antibodies (aINI1, aPPARg2) then PCR amplification of the aP2 promoter sequence. Flag antibody (aFlag) was used as a negative control. McBeath et al., 2004) . The study of the osteogenic and chondrogenic potentials of MRTs may give insights into the degree of commitment of MRTs into the various mesenchymal lineages. However, the differentiation potential of MRTs may not be limited to these lineages since we previously showed that some MRT cell lines can differentiate along the neural lineage (Albanese et al., 2006) . In particular, this study showed that MON cells present primitive polyphenotypic features and exhibit mild neural differentiation characteristics upon hSNF5/INI1 expression and incubation with differentiation agents. Together with the present report, our results indicate that, depending upon in vitro growth conditions, the same MON cell line harbors both neural and adipocyte differentiation potentials. With respect to this neural potential, a recent report, in a murine model of MRTs, suggests that these tumors may arise from a subset of spinal cord neural progenitor cells (Chai et al., 2007) . Interestingly, mesenchymal and neural potentials have recently been linked since MSCs may both originate from a neural crest intermediate stage (Takashima et al., 2007) and differentiate into neural cells (Krabbe et al., 2005) . Finally, the question of an even more primitive progenitor for MRTs is raised by the observation that atypical teratoid and rhabdoid tumors of the central nervous system, can exhibit positive areas for epithelial, neural and mesenchymal markers within the same tumor (Lee et al., 2002) . It therefore remains to be determined whether MRTs arise from a single pluripotent progenitor or from different progenitors committed to various lineages. The analysis of other in vitro differentiation models and of in vivo targeting of Snf5/Ini1 knockout in specific organs may enable the issues of the progenitor cell(s) and of the requirement of hSNF5/INI1 in various differentiation pathways to be further investigated. Finally, SNF5/INI1 loss induces tumorigenesis in some specific and permissive cellular backgrounds, whereas it is lethal in others (Roberts et al., 2002) . In this study, we observe that SNF5/INI1 knock down is deleterious neither for 3T3-L1-committed preadipocytes nor for MSCs. Rather, it increases proliferation of 3T3-L1 cells. Although we cannot exclude that the residual expression of SNF5/INI1 following RNA interference may be sufficient for survival, this may also indicate that these cells are permissive to SNF5/INI1 loss, an expected characteristic for the MRT progenitor cell.
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In conclusion, these results give new insights into the mechanisms of tumor suppression by SNF5/INI1. They reveal that hSNF5/INI1 re-expression couples proliferation arrest with the induction of differentiation in MRT cell lines, suggesting that SNF5/INI1 tumor suppressor role may rely on its ability to regulate the balance between cell proliferation and differentiation.
Materials and methods
Cell culture and differentiation assays MRT cell lines (MON and KD, established from abdominal MRTs and Wa2 from a spinal MRT) were grown in RPMI supplemented with 10% fetal calf serum (FCS). The tetracycline-regulated hSNF5/INI1-inducible cell line I2a was maintained and induced as described previously (Medjkane et al., 2004) . 293T and 3T3-L1 cells (ATCC) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FCS or bovine serum respectively. To induce differentiation, 3T3-L1 cells were grown to confluence and the medium was supplemented with 10% FCS, 1 mg ml À1 insulin, 0.5 mM isobutyl methyl xanthin, 1 mM dexamethasone for 2 days, then with 1 mg ml À1 insulin only. Human primary mesenchymal stem cells (MSCs) prepared from bone marrow were a gift from Pierre Charbord (Laboratoire d'He´matopoı¨e`se, Faculte´de Me´decine, Tours, France) and cultured in MEMa supplemented with 10% FCS. Differentiation of MSCs or MRTs was induced in medium containing 0.5 mM isobutyl methyl xanthin, 60 mM indomethacine and 1 mM dexamethasone (Dennis and Charbord, 2002) .
Senescence-associated b-galactosidase staining Cells were fixed in 3.7% formaldehyde in PBS and incubated overnight in a 37 1C (no CO 2 ) incubator in b-Gal solution (5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 40 mM sodium citrate, pH 4 or 6, 100 mM sodium phosphate, pH 4 or 6, 2 mM MgCl 2 , 150 mM NaCl and 1 mg ml À1 X-Gal).
Transfections and reporter assays HA-INI1-, HA-INI1D1-, HA-INI1D2-and HA-INI1D3-pCDNA3 encoding vectors as well as the MRT cells transfection procedure by Effectene reagent (Qiagen, Courtaboeuf, France) have been described previously (Versteege et al., 2002) . Transfected cells were selected with G418 (200 mg ml
À1
). Human PPARg2 promoter (1000 bp) in pGL3-Luc vector, pMEX-C/EBPb and pSG5-PPARg2 expression vectors were provided by Dr Johan Auwerx (IGBMC, Strasbourg, France). Murine aP2 promotor (À2900/ þ 21 bp) was PCR-amplified from bluescript-aP2 (provided by Dr Ruth White, Harvard) and cloned into the pGL3-Luc vector (Promega, Charbonnie`res, France). Luciferase reporter activity assays were performed as described previously (Saladin et al, 1999) with Dual-Luciferase reporter assay (Promega).
Retroviral and lentiviral infections
For retroviral-mediated expression of hSNF5/INI1, HA-INI1-encoding sequence was PCR amplified from the pCDNA-HA-INI1 vector and cloned between the BamHI and XhoI restriction sites of the retroviral pWZL-IRES-Blast vector (obtained from Anna Marie Kenney, Boston, MA, USA). For knocking-down murine Snf5/Ini1 in 3T3-L1 or human SNF5/ INI1 in primary MSCs, the Mission TRC shRNA clone nos. 87857 and 39587 were used respectively (SMARCB1, pLKO.1-puro, Sigma, Lyon, France). Viral particles were produced in 293T cells transfected with appropriate packaging plasmids by the calcium phosphate method. Viral supernatants were then supplemented with 8 mg ml À1 polybrene for infection and blasticidin (8 mg ml À1 for MON and KD, 12 mg ml À1 for Wa2) or puromycin (1 mg ml À1 for MSCs and 2 mg ml À1 for 3T3-L1) was added 48 h later.
Flow cytometry for cell-cycle analyses Cell-cycle analyses were performed by BrdU incorporation as described previously (Versteege et al., 2002) . Samples were subjected to FACS analysis (FACScalibur, BD Biosciences, Le Pont-de-Claix, France) and the data processed using FlowJo software.
Coimmunoprecipitation experiments and western blot analyses
Coimmunoprecipitation experiments and SDS-PAGE electrophoresis were performed as described previously (Medjkane et al., 2004) . Mouse anti-INI1 (BD Bioscience), mouse antib-actin (Sigma), rabbit anti-BRG1 (H88 Santa-Cruz, Tebu, Paris, France), goat anti-BAF155 (R18 Santa-Cruz), rabbit anti-BAF-170 (provided by Dr Christian Muchardt) and rabbit anti-C/EBPb (C19-Santa Cruz) were used. HRPconjugated anti-mouse, anti-rabbit or anti-goat secondary antibodies were from Amersham (Orsay, France).
Oil Red O staining Cells were fixed with 3.7% formaldehyde (Sigma) for 5 min, then stained with 0.3% (w/v) Oil Red O (Sigma) in 60% isopropanol for 15 min and washed extensively with water. After drying, nuclei were stained with hematoxylin (150 mg ml À1 ) for 2 min.
Real-time quantitative reverse transcription-PCR analyses Total RNA was extracted using Trizol reagent (Invitrogen, Cercy-Pontoise, France). DNAseI treatment (Roche, Meylan, France) was carried out when required, for 30 min at 37 1C. cDNAs were synthesized from 1 mg of RNA using the GeneAmp RNA PCR core Kit (Applied Biosystem). Quantitative PCR analyses were performed using either TaqMan Assays-on-demand with qPCR Mastermix Plus without UNG, or specific primers with Sybr Green PCR Master Mix (Applied Biosystem, Foster City, CA, USA). Reactions were run on an ABI/PRISM 7500 and analysed using the 7500 system SDS software. GAPDH expression, which does not vary with the experimental conditions, was used for normalization. The following assays-on-demand were used for human gene expression study: PPARg2 (Hs00234592_m1), LPL (Hs00173425_m1), aP2 (Hs00609791_m1), C/EBPa (Hs00269972_s1), C/EBPb (Hs00270923_s1), GAPDH (Hs99999905_m1). For the murine genes, the following primers were used: PPARg2 (5 0 -GCTGTT ATGGGTGAAACTCT-3 0 , 5 0 -TGGCATCTCTGTGTCAAC CA-3 0 ), LPL (5 0 -TAGACAACGTCCACCTCTTAG-3 0 , 5 0 -GTAAGACATCTACAAAATCAGC-3 0 ), adipsin (5 0 -CGGGG TAGTCACCATTAACA-3 0 , 5 0 -CTTTTTGCCATTGCCACA GA-3 0 ), GAPDH (5 0 -AAAATGGTGAAGGTCGGTGT-3 0 , 5 0 -TGACTGTGCCGTTGAATTTG-3 0 ).
Chromatin immunoprecipitation
Cells (4 Â 10 6 ) were crosslinked in 1% formaldehyde at room temperature for 7 min. Cells were then collected in lysis buffer (1% Triton X-100, 0.1% SDS, 2 mM EDTA, 20 mM Tris-HCl, pH 8, 150 mM NaCl, containing protease inhibitors) and cell lysates were sonicated for 10 min at 20% duty. Cell lysates precleared with protein A-Sepharose were immunoprecipitated at 4 1C overnight with 15 ml of anti-INI1 (kindly provided by Antony Imbalzano), or with 10 mg of anti-C/EBPb (Santa Cruz sc-7962), anti-PPARg2 (Santa Cruz sc-7273) or anti-Flag (Sigma) antibodies. Immune complexes were then collected by incubation with protein A-Sepharose for 2 h and beads were washed sequentially with lysis buffer, containing 500 mM NaCl, with LiCl buffer (0.25 M LiCl, 1% NP40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8) and finally with TE. Elution was performed with 1% SDS in TE and crosslinks were reversed by heating at 65 1C overnight. After treatment with proteinase K, DNA was extracted with phenol/chloroform, precipitated with ethanol and resuspended in 10 ml of TE. One-tenth of immunoprecipitated DNA and 1% of the input DNA were used for 30 cycles of PCR amplification, using PPARg2 (À251 AGTGGATATTGAAC AGTCTC, À45 ATAAACACAGAAAGGACTGG) and aP2 (ACTGAGGGTCTGGGGCTATGTCC, GTTCCTGGCA CCTGGTTCTTCAC) promoter-specific primers spanning C/EBP and PPARg binding sites respectively.
